A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The study will compare the pharmacokinetic profile of OvaRex MAb-B43.13 ascites fluid product and OvaRex MAb-B43.13 cell culture product. Safety and immune responses following treatment with the cell culture product will be evaluated.
Epistemonikos ID: 2a57b0aa5dc90435e27f79060a14876e2d4ad00d
First added on: May 03, 2024